Reviewing Crinetics Pharmaceuticals (NASDAQ:CRNX) & Carisma Therapeutics (NASDAQ:CARM)

Crinetics Pharmaceuticals (NASDAQ:CRNX) and Carisma Therapeutics (NASDAQ:CARM) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation and earnings.

Volatility and Risk

Crinetics Pharmaceuticals has a beta of 0.33, indicating that its share price is 67% less volatile than the S&P 500. Comparatively, Carisma Therapeutics has a beta of 1.79, indicating that its share price is 79% more volatile than the S&P 500.

Profitability

This table compares Crinetics Pharmaceuticals and Carisma Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Crinetics Pharmaceuticals	N/A	-32.28%	-29.45%
Carisma Therapeutics	-254.28%	N/A	-211.28%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Crinetics Pharmaceuticals and Carisma Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crinetics Pharmaceuticals	0	2	7	0	2.78
Carisma Therapeutics	0	4	1	2	2.71

Crinetics Pharmaceuticals currently has a consensus target price of $68.8571, indicating a potential upside of 131.92%. Carisma Therapeutics has a consensus target price of $1.9250, indicating a potential upside of 574.73%. Given Carisma Therapeutics’ higher probable upside, analysts plainly believe Carisma Therapeutics is more favorable than Crinetics Pharmaceuticals.

Institutional & Insider Ownership

98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are owned by institutional investors. 4.6% of Crinetics Pharmaceuticals shares are owned by insiders. Comparatively, 6.9% of Carisma Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Crinetics Pharmaceuticals and Carisma Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crinetics Pharmaceuticals	$1.04 million	2,688.66	-$298.41 million	($4.11)	-7.22
Carisma Therapeutics	$19.63 million	0.61	-$60.48 million	($1.56)	-0.18

Carisma Therapeutics has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Carisma Therapeutics beats Crinetics Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

About Carisma Therapeutics

Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.